Skip to main content
Caplight Logo









Biomunex Pharmaceuticals

Biomunex Pharmaceuticals

Private
ParisHealthcare & Life Scienceshttps://biomunex.com/

Last Round

VC Round

Sep 30, 2025

Total Funding Raised

$3.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Biomunex Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of innovative immuno-therapeutics, including bi- and multi-specific antibodies for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

bispecific antibodyimmuno-oncologyMAIT cell engagersantibody engineeringdrug discoverybiotech platformin-silico drug designmulti-specific antibodycancer immunotherapybiopharma licensingai-augmented drug discoveryprotein engineeringnext-gen biologicst-cell engagers

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Biomunex Pharmaceuticals Comparables

Compare Biomunex Pharmaceuticals with similar companies based on industry and business-model similarity.

Biomunex Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sino Biopharmaceutical
78%
Merus N.V.
76%
TRIO Pharmaceuticals, Inc.
76%

Biomunex Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundSep 30, 2025
GrantNov 3, 2021
Series AFeb 16, 2021

Key People

Founding team and executive leadership

Stéphane MILOT

Chief Financial Officer

Executive Team

Biomunex Pharmaceuticals Investors

Notable investors and investment history

Biomunex Pharmaceuticals investors
InvestorRounds
Agence Nationale de la RechercheGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors increased 83% MoM.

  • May 8, 2026

    Grew 20% QoQ, from 15 to 18 employees.

Biomunex Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Biomunex Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Biomunex Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range19
Year Founded2014
Last FundingSep 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?